Vanguard Global Advisers
REGN icon

Vanguard Global Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Vanguard Global Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141M Sell
226,724
-1,767
-0.8% -$1.2M 0.07% 222
2026
Q1 		$177M Buy
+228,491
New +$175M 0.09% 169

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Global Advisers's REGN Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 0.77% in Q2 2026, selling an estimated $1.2M and leaving 226,724 shares worth $141M. The position accounts for 0.07% of the portfolio, ranked #222.

Vanguard Global Advisers first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $177M in Q1 2026. 1,256 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Vanguard Global Advisers held 226,724 shares of Regeneron Pharmaceuticals worth $141M as of Q2 2026.
  • Vanguard Global Advisers sold 1,767 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
  • Regeneron Pharmaceuticals made up 0.07% of Vanguard Global Advisers's portfolio in Q2 2026, its #222 holding.
  • Vanguard Global Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Regeneron Pharmaceuticals position peaked at $177M in Q1 2026.
  • 1,256 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.